AU2003218462A8 - Treatment of obesity and other disorders associated with excessive food intake - Google Patents
Treatment of obesity and other disorders associated with excessive food intakeInfo
- Publication number
- AU2003218462A8 AU2003218462A8 AU2003218462A AU2003218462A AU2003218462A8 AU 2003218462 A8 AU2003218462 A8 AU 2003218462A8 AU 2003218462 A AU2003218462 A AU 2003218462A AU 2003218462 A AU2003218462 A AU 2003218462A AU 2003218462 A8 AU2003218462 A8 AU 2003218462A8
- Authority
- AU
- Australia
- Prior art keywords
- obesity
- treatment
- food intake
- disorders associated
- excessive food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPCT/US2002/031294 | 2002-10-01 | ||
| PCT/US2002/031294 WO2003029210A2 (en) | 2001-10-04 | 2002-10-01 | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| PCT/US2002/040147 WO2003051833A2 (en) | 2001-12-18 | 2002-12-13 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| PCT/US2002/041720 WO2003051315A2 (en) | 2001-12-18 | 2002-12-13 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| AUPCT/US2002/041720 | 2002-12-13 | ||
| AUPCT/US2002/040147 | 2002-12-13 | ||
| PCT/US2002/040237 WO2003053922A2 (en) | 2001-12-19 | 2002-12-16 | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| AUPCT/US2002/040237 | 2002-12-16 | ||
| PCT/US2002/040486 WO2003059904A1 (en) | 2001-12-21 | 2002-12-17 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| AUPCT/US2002/040486 | 2002-12-17 | ||
| PCT/US2003/009717 WO2004030637A2 (en) | 2002-10-01 | 2003-03-31 | Treatment of obesity and other disorders associated with excessive food intake |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003218462A1 AU2003218462A1 (en) | 2004-04-23 |
| AU2003218462A8 true AU2003218462A8 (en) | 2004-04-23 |
Family
ID=32074735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003218462A Abandoned AU2003218462A1 (en) | 2002-10-01 | 2003-03-31 | Treatment of obesity and other disorders associated with excessive food intake |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003218462A1 (en) |
| WO (1) | WO2004030637A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2591003A1 (en) * | 2004-12-27 | 2006-07-06 | Astrazeneca Ab | Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders |
| US20120309792A1 (en) * | 2009-12-18 | 2012-12-06 | Neurosearch A/S | Tetrazole derivatives as nicotinic acetylcholine receptor modulators |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| BR112015023279B1 (en) | 2013-03-13 | 2021-01-19 | Forma Therapeutics, Inc. | compounds for fasn inhibition |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN112020500A (en) | 2017-12-22 | 2020-12-01 | 拉文纳制药公司 | Aminopyridine derivatives as inhibitors of phosphatidylinositol phosphokinase |
| TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
| EP3873214A4 (en) | 2018-10-29 | 2022-07-13 | Forma Therapeutics, Inc. | Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| TW202112767A (en) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| PL442982A1 (en) * | 2022-11-29 | 2024-06-03 | Uniwersytet Medyczny W Lublinie | N-substituted derivatives of 1-(1-phenyl-3-aryl)-1H-pyrazol-4-yl)methanamine, method of their preparation and use |
-
2003
- 2003-03-31 WO PCT/US2003/009717 patent/WO2004030637A2/en not_active Application Discontinuation
- 2003-03-31 AU AU2003218462A patent/AU2003218462A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003218462A1 (en) | 2004-04-23 |
| WO2004030637A3 (en) | 2004-09-23 |
| WO2004030637A2 (en) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003290548A8 (en) | Prevention and treatment of synucleinopathic disease | |
| AU2003233583A8 (en) | Oral lactoferrin in the treatment of respiratory disorders | |
| EP1489915A4 (en) | Treatment and prevention of inflammatory disorders | |
| EP1706108A4 (en) | Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity | |
| EP1575480A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1578367A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1572116A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1576137A4 (en) | Compositions and methods for the treatment of immune related diseases | |
| EP1589960A4 (en) | Treatment of obesity and associated conditions with tgf-beta inhibitors | |
| PT1711070E (en) | Nutritional composiition for improving skin condition and preventing skin diseases | |
| EP1539138A4 (en) | Therapeutic process for the treatment of obesity and associated metabolic disorders | |
| EP1560593A4 (en) | Novel composition and methods for the treatment of immune related diseases | |
| EP1684739A4 (en) | Treatment and prevention of liver disease associated with parenteral nutrition (pn) | |
| AU2003218462A8 (en) | Treatment of obesity and other disorders associated with excessive food intake | |
| AU2003299823A8 (en) | Methods of inducing and maintaining immune tolerance | |
| ZA200702421B (en) | Iron complex for use in the treatment and/or prevention of nutritional disorders | |
| EP1581095A4 (en) | Therapeutic methods for reducing fat deposition and treating associated conditions | |
| GB0128674D0 (en) | Treatment of sleep disorders and the like | |
| AU2003233681A8 (en) | Diagnosis and treatment of human dormancy syndrome | |
| AU2003209289A8 (en) | Transposable elements in rice and methods of use | |
| AU2003221845A8 (en) | Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction | |
| EP1802350A4 (en) | Modulation of neuroglia-derived bdnf in the treatment and prevention of pain | |
| HK1041769A2 (en) | A health care food useful for maintaining the health of the intestinal tract and be helpful in reducing the obesity in the abdomen | |
| AU2003270815A8 (en) | Treatment of irritable bowel syndrome and related bowel diseases | |
| AU2003270540A8 (en) | Treatment of cyclooxygenase-3 mediated diseases and disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |